2023 Targeted Therapies of Lung Cancer Meeting

Program at a Glance

Registration is open for #TTLC23! After 2 yrs of virtual meetings, we are thrilled to invite you to join us again in a face-to-face meeting w/virtual elements to enhance participant’s experience & allow anyone from anywhere to join. Register Now: https://bit.ly/3OuOJ8O #LCSM

Fact: As of 2020, the #lungcancer survival rate increased 14.5% over the last five years nationally to 23.7%, yet remains significantly lower among communities of color at 20.0%, and Black Americans at 18.0%. #LCAM22 #LCSM

This guideline reflects a new staging system for people with #thymoma and #thymiccarcinoma which includes recommendations developed to improve management of #thymic epithelial tumors in patients.
https://bit.ly/3GDqHXp #LCSM

The #EUCancerPlan introduced new #lungcancer screening recommendations based on the latest technology, scientific developments & evidence in 3 key areas: access, quality, & diagnostics with a focus on increasing the number of earlier diagnoses. https://bit.ly/3ghtnip #LCAM22

Load More

View TTLC 2023 Program at a Glance

This program is a preliminary version and is subject to change without notice.